Janssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes

Update: Invokana (canagliflozin) Now FDA Approved - March 29, 2013

NEW BRUNSWICK, N.J., June 5, 2012 /PRNewswire/ -- Janssen and Johnson & Johnson (NYSE: JNJ) will provide investors and other interested parties an overview presentation of results from five pivotal Phase 3 studies evaluating investigational canagliflozin for the treatment of Type 2 Diabetes on Sunday, June 10 at approximately 2:00 p.m., Eastern Time. These data will be presented at the American Diabetes Association annual meeting in Philadelphia, Pa.

The presentation can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."

SOURCE Johnson & Johnson

 
CONTACT: Press, Al Wasilewski, +1-732-524-1130, Bill Price, +1-732-524-6623, or Investor, Stan Panasewicz, +1-732-524-2524, Louise Mehrotra, +1-732-524-6491

Web Site: http://www.jnj.com

 

Posted: June 2012

View comments

Hide
(web4)